MXC: $0.052
A Brief History of MGC Pharma

In May 2015, MGC Global was listed on the ASX following a reverse takeover deal with former gold explorer company, Erin Resources. Two years later, and MGC has undertaken groundbreaking research, come to strategic agreements with leading academia around the world and global companies, developed the highest quality products for our patients and and created our own premium Dermatological Cosmetic Cannabidiol Company. Discover MGC’s remarkable and forging history below.

May 2019

Arrival of first CannEpilTM shipment to United Kingdom

May 2019
Distribution Agreement with Grow Biotech and IPS to provide immediate access to large UK Medical Cannabis Market
page1image1584233344
May 2019

New Distribution Agreements signed for CannEpilTM, CogniCannTM, MXP100 and MXC1:1 products in Australia

page1image1582909136

April 2019

Agreement signed to market and distribute MGC Nutraceuticals CBD based products into Chinese health products market

April 2019

United Kingdom Controlled Drug Import Licence received for the importation of CannEpilTM into the UK

March 2019

European corporate and pharmaceutical industry expert Dr. Stephen Parker appointed Non-Executive Director

page1image2514570016

February 2019

MXC successfully develops new proprietary genetic strain; MXC-10, containing high levels of THC (>35%)

January 2019

Completion of MGC Derma Sale to CannaGlobal

January 2019

TGA approval for CogniCannTM use during a clinical trial

December 2018

First CannEpilTM Product arrives in Australia.

December 2018

MGC Pharmaceuticals commences trading in the US on the OTCQB Venture Market

November 2018
MXC has signed a partnership agreement with the Royal Melbourne Institute of Technology (RMIT) and The Hebrew University of Jerusalem (HUJ) to create and launch ‘CannaHub’, an international research hub for medicinal cannabis.
October 2018

CannEpilTM available for Australian supply under Authorised Prescriber Scheme

page1image217774480

September 2018
Sale of MGC Derma to Strategic Partner Cannaglobal Canada
August 2018

Ethics Approval received for Australian Phase II Clinical Trial into Dementia.

July 2018

MXC has been awarded formal GMP Certificate and manufacturing license

April 2018

Malta Government gives approval for Licensed Medical Cannabis Facility

March 2018

MXC Launches MGC Nutraceuticals Product Line

February 2018

MGC Derma Product Officially Launched on Cult Beauty

January 2018

MGC Derma launches CBD Herbal Psoriasis Cream

January 2018

Initial GMP Certification for European Production Facility

November 2017

Binding Agreement to Supply $1m CBD Extract Annually

November 2017

Definitive Supply Agreement Executed with HL Pharma

November 2017

First Varm Cosmo Binding Purchase Order Received

November 2017

MXC Enters Multi $M Australian Pharma Market

October 2017

$40 Million White-Label CBD Cosmetics Agreement Executed

June 2017

First European Distribution deal signed for API products

June 2017

EU Medical Cannabis License granted with Strategic Agreement

May 2017

Strategic exclusive Agreement Signed with RMIT University to study the effects of Medical Cannabis on melanoma and other cancers.

May 2017

New CEO appointment of Roby Zomer

May 2017

New EU Sales Agreements Signed For MGC Derma

April 2017

European API Extraction Facility Completed

February 2017

MGC Pharmaceuticals Ltd acquired an 80% share of Czech Medical Cannabis company Panax Pharma s.r.o with option to buy remaining 20% share.

February 2017

Australian Legislation Changed Fast Track MXC

January 2017

Dermatological Clinical Trials Commenced

January 2017

European CPNP Approval Granted for Derma Products

December 2016

First Major European Sales and Revenue for MGC Derma Range

November 2016

EU Registration Commenced for CBD Derma Product Sales

September 2016

New Medical Cannabis White Paper Developed with University of Sydney

September 2016

Strategic Agreement signed with Epilepsy Action Australia

May 2016

Clinical study on children and adolescents with treatment-resistant epilepsy at Ljubljana University Medical Centre (Ljubljana UMC)  Efficacy study to test MGC Pharmaceuticals’ medicinal Cannabis formulation. Compares MXC proprietary whole plant extract based medicine with high CBD/THC ratio to pure synthetic CBD.

May 2016

An outdoor growing and extraction facility was established by  MGC Pharmaceuticals Ltd. in Slovenia in partnership with research and development business, Natura Laboratories Ltd. to develop high quality products for the cosmetics and pharmaceutical industries.

May 2016

Health Canada Approved MGC Derma CBD Cosmetics

May 2016

FDA Approval Granted and First US Distribution Deal Signed

May 2016

European Commission Approves MGC Derma Cosmetics Products

May 2016

MGC Pharmaceuticals Ltd. executed a binding of heads of Agreement (HOA) to acquire Czech- based Medical Cannabis company, PANAX Pharma s.r.o. (Panax) which enabled indoor operations via the Vukoz Institute research facility

April 2016

Launch of Online Store, www.mgcderma.com – First Retail Sales of CBD Cosmetics Recorded.

April 2016

MXC to Acquire Licensed European Medical Cannabis Company

March 2016

MXC Secured First Cosmetics Sales Agreement

March 2016

MXC Publishes First Australian Medical Cannabis White Paper

March 2016

MGC Pharmaceuticals Ltd. (ASX:MXC) took the first step into the world of pharmaceuticals, following research out of the Hadassah Medical Centre in Israel. An R&D agreement was developed with Israeli company, Sipnose, to develop technology which can transport  pharmaceuticals directly to the brain.

February 2016

Acquisition of MGC Pharma (UK) by MGC Pharmaceuticals Ltd.

December 2015

Change of Company Name to MGC Pharmaceuticals Ltd, formerly known as Erin Resources Limited.

May 2015

MGC Global was listed on the ASX following a reverse takeover deal with former gold explorer company, Erin Resources.